1. The market is correcting, not collapsing

Speaker credit: Jeff Myers, Nader Elrashidy

The life sciences market has clearly moved out of its peak-growth phase, but that does not mean the sector is broken. The better read is that the market is recalibrating after several years of rapid expansion, heavy investment, and aggressive development.

Jeff Myers noted that occupied life sciences space is still meaningfully higher than it was at the start of the cycle, even after some recent pullback. Nader Elrashidy echoed this from the innovation side, describing the current environment as a period of normalization. The market is more disciplined now, but the underlying demand drivers have not disappeared.

2. Vacancy is being driven more by oversupply than by a lack of long-term demand

Speaker credit: Jeff Myers

One of the clearest themes from Jeff Myers’ research presentation was that rising vacancy is not simply a demand problem. It is also a supply problem.

During the last growth cycle, many major life sciences markets added a significant amount of new inventory. In several cases, new supply came online faster than leasing activity could absorb it. That imbalance has pushed vacancies higher, particularly in markets like Boston, San Diego, and the San Francisco Bay Area, where development activity was especially strong.

The takeaway is clear: demand remains, but the market is still absorbing the volume of space delivered during the boom.

3. Tenants have more options, and more leverage, than they have had in years

Speaker credit: Jeff Myers, David Burden, Frank Petz

For tenants, this market looks very different from what it did a few years ago. Instead of fighting for limited space in a landlord-favorable environment, companies now have access to more high-quality options across several major markets.

Jeff Myers pointed to the amount of available newly built or recently delivered space. David Burden added that some owners are now taking the deals available in the market, including office users in certain lab-oriented assets. Frank Petz also framed the pricing reset as an opportunity for users and investors who are ready to act.

The practical takeaway: tenants that understand their space needs and capital position may be able to secure better terms, better buildings, and more flexibility than they could during the peak.

4. Capital is coming back, but it is coming back carefully

Speaker credit: Jeff Myers, Frank Petz, Nader Elrashidy

There are signs of renewed capital activity across the life sciences sector, including improving IPO activity, more M&A, and increased venture capital volume compared to the market lows. But the capital environment has changed.

Investors are more selective. They are looking harder at proof of concept, stronger data, later-stage opportunities, and a clearer path to commercialization. Nader Elrashidy emphasized that companies need to show credible progress and ROI potential, while Jeff Myers noted that fewer deals are being funded even as overall volume improves.

In other words, capital remains available, but investors are applying greater discipline, asking more detailed questions, and prioritizing companies with clearer paths to commercialization.

5. AI is becoming a serious market driver, not just a buzzword

Speaker credit: Jeff Myers, Rob Albro, Nader Elrashidy, Joe Fetterman

AI is beginning to reshape both the biotech sector and the real estate that supports it.

Jeff Myers highlighted the growing share of venture-funded life sciences companies tied to AI and machine learning. Rob Albro discussed the impact of AI, robotics, and broader technology demand, particularly in markets like the Bay Area. Nader Elrashidy connected AI to computational biology, wet lab validation, and the “lab-in-the-loop” model. Joe Fetterman added that AI could change how much bench work is needed while also creating new opportunities for company formation.

The key point is that AI is not replacing the life sciences real estate story. It is changing the way that the story gets built.

6. Flexibility matters more than ever

Speaker credit: Frank Petz, Rob Albro, Nader Elrashidy, Joe Fetterman

The market is moving away from the idea that a building only needs to be “lab space” to be valuable. The next phase of demand will reward buildings that can support multiple uses, including lab, office, automation, robotics, advanced manufacturing, and other technology-driven work.

Frank Petz made this point clearly, noting that “just lab” is no longer the automatic answer. Rob Albro emphasized the growing importance of power. Nader Elrashidy pointed to automated environments and leaner startup platforms. Joe Fetterman added that AI may change how companies use lab and bench space over time.

For owners and developers, the takeaway is clear: single-purpose buildings may carry more risk in a market where the tenant profile is evolving.

7. Biomanufacturing is one of the stronger growth lanes

Speaker credit: Jeff Myers, Rob Albro, Joe Fetterman, Nader Elrashidy

While traditional R&D leasing has slowed in many markets, biomanufacturing and advanced manufacturing are showing stronger momentum.

Jeff Myers pointed to Raleigh and North Carolina as examples of markets benefiting from major manufacturing investment and onshoring activity. Rob Albro discussed King Street’s focus on biomanufacturing and advanced manufacturing, including activity in North Carolina. Joe Fetterman noted that many active projects he is seeing are manufacturing-related, including build-to-suit opportunities. Nader Elrashidy also highlighted major pharmaceutical investment in U.S. manufacturing and radiopharma.

This is one of the clearest bright spots in the market. R&D may still be working through its slowdown, but manufacturing demand has a different set of drivers and appears to be moving with more urgency.

8. Pricing has reset, and distress will create opportunity

Speaker credit: Frank Petz, Rob Albro, David Burden

The capital markets conversation was direct: values have come down, return requirements have gone up, and some owners are still adjusting to the new reality.

Frank Petz spoke to the sharp pricing reset in life sciences real estate, including assets that would trade far below peak pricing today. Rob Albro discussed how underwriting has become more conservative, particularly around lease-up assumptions and stabilized occupancy. David Burden added context around assets trading below replacement cost, especially in markets where purpose-built lab buildings remain vacant.

This creates challenges for some owners, but opportunities for others. Investors with capital, patience, and conviction may find assets they could not have touched a few years ago.

9. Strong ecosystems will separate the winners from the rest

Speaker credit: Jeff Myers, Rob Albro, David Burden

Not every market with available space is equally positioned for recovery. The markets with the strongest long-term prospects are those with deep ecosystems: universities, hospitals, research talent, venture capital, pharma presence, and existing industry infrastructure.

Jeff Myers emphasized the importance of these ecosystem drivers and pointed to markets such as Boston, the Bay Area, San Diego, New York, Chicago, Raleigh, Philadelphia, and Houston as markets to watch in different ways. Rob Albro reinforced the importance of focusing on markets with established life sciences foundations. David Burden helped frame the discussion around which markets may move from emerging to more established.

The takeaway: buildings matter, but ecosystems matter more.

10. The long-term story is still about innovation

Speaker credit: Nader Elrashidy, Joe Fetterman, Jeff Myers

While the real estate market continues to recalibrate, scientific innovation continues to advance.

Nader Elrashidy pointed to progress in oncology, obesity, neurology, precision medicine, radiopharmaceuticals, AI-enabled discovery, and global innovation. He also highlighted China’s growing role in biotech innovation and licensing activity. Joe Fetterman added that closer engagement between pharma and early-stage discovery could help accelerate R&D over time. Jeff Myers connected these innovation trends back to funding, company formation, and future demand.

The broader message is that short-term market dislocation should not be confused with long-term weakness. Life sciences remains a high-risk, high-reward sector, but the innovation pipeline is still active. The next cycle will likely favor companies, investors, developers, and markets that can adapt to a disciplined, technology-integrated environment.